Compare Msci Inc (MSCI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Novartis AG — how do they compare? Msci Inc trades at $562 (market cap $40.94B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 7.3× Msci Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| MSCI | NVS | |
|---|---|---|
Market Cap | $40.94B | $298.18B |
Sector | Financials | Health |
52-Week High | $643.83 | $168.62 |
52-Week Low | $511.84 | $119.31 |
Enterprise Value | $47.10B | $339.50B |
Dividend Yield | 1.46% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.17, down 0.72% with bearish technical signals but strong fundamentals including 40.73% net margins and consistent earnings beats. The company shows robust revenue growth from $2.2B in 2022 to $3.13B in 2025, with positive cash flow trends. Recent acquisitions like First Street and partnerships with UBS enhance its private markets platform, supporting long-term growth in climate risk analytics and alternative investments.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $728.14 consensus target, implying 29% upside. Key risks include high debt levels at $4.51B and sensitivity to market cycles, but recurring revenue models and strategic expansions position MSCI for sustained outperformance despite near-term technical weakness.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
